The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > BUSINESS
BUSINESS
- Kidswell Bio Revs Up Biosimilar Push, G-Lasta, Eylea Follow-Ons in Development
February 22, 2023
- Pfizer Files RSV Vaccine in Japan
February 21, 2023
- FDA Target Date for Hot Flash Med Extended by 3 Months: Astellas
February 21, 2023
- Japan Approves Taisho’s Visceral Fat-Reducing Med as Nonprescription Drug
February 20, 2023
- US Patent Office Restarts PGR for Seagen Patent: Daiichi Sankyo
February 20, 2023
- PharmaEssentia Lays Out Sales Organization in Japan for 1st Product Launch
February 20, 2023
- Susmed Bags Japan Approval for Insomnia App
February 20, 2023
- IQVIA Pledges Push to Biopharma Startups in Japan
February 20, 2023
- Global PIII Launched for Xocova in Hospitalized Patients: Shionogi
February 20, 2023
- Mitsubishi Chemical Ups Full-Year Outlook on Gilenya Royalty Win
February 20, 2023
- Shareholders OK Nichi-Iko’s Delisting, Turnaround under New Management; President to Exit March 8
February 20, 2023
- Healios Cuts 40 % of Employees Due to MultiStem Development Glitches
February 17, 2023
- Nippon Shinyaku Grabs Japan Rights to Capricor’s DMD Cell Therapy
February 17, 2023
- ViiV Eyes More Uptake for Japan’s 1st Long-Acting HIV Med, Revs Up Development Drive
February 17, 2023
- As Global Race Heats Up for RAS Drugs, Japan Players Joining Fray with New Modalities
February 15, 2023
- Mitsubishi Tanabe Wins Arbitration Case over Gilenya Royalty
February 15, 2023
- Otsuka’s Pharma Sales Up 16.4% in 2022 on Global Brands, Hits 2023 Target 1 Year Earlier
February 15, 2023
- Fujifilm Begins Japan PIII for Stem Cell Therapy in Meniscus Injuries
February 15, 2023
- Mitsubishi Chemical Scraps Muse Cell Therapy Program
February 15, 2023
- Sawai President Sounds Negative about M&As, but Agrees Generic Industry Needs Consolidation
February 14, 2023
ページ
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…